

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

AUMOLERTINIB MESILATE TABLETS WAS APPROVED BY THE MHRA FOR MARKETING

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®), the Group’s innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency (“**MHRA**”) in the UK for marketing. Aumseqa® as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (“**NSCLC**”) with activating epidermal growth factor receptor (“**EGFR**”) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

About Aumolertinib Mesilate Tablets

Aumolertinib Mesilate Tablets (trade name in China: 阿美樂®) is the first innovative third-generation EGFR-TKI drug wholly developed in China. It has been approved for four indications in China, namely: in March 2020, it was approved for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy; in December 2021, it was approved as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive; in March 2025, it was approved for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations; in May 2025, it was approved for the adjuvant treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and who have undergone tumor resection with or without prior adjuvant chemotherapy as determined by their physician.

One additional NDA of Ameile has been accepted by the National Medical Products Administration (NMPA) of China, namely: in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, June 4, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.